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ABStrACt
Background: Nicotine replacement therapy (NRT) helps smokers quit smoking, but trials indicate that there is no evidence 
that it is effective in pregnancy. As metabolism increases during pregnancy, NRT may deliver insufficient nicotine to alleviate 
withdrawal symptoms. There is mixed evidence as to what levels of cotinine are reached from nicotine exposure in pregnancy 
while using NRT, compared with smoking.
Methods: We analyzed data on 33 pregnant participants from the NRT arm of a randomized control trial who had stopped 
smoking and were still using 15 mg/16 hr nicotine patches 1 month after quitting. Salivary cotinine levels when smoking at base-
line were compared with levels on NRT at 1 month using the Wilcoxon test.
results: Cotinine levels were a median of 98.5 ng/ml while smoking and 62.8 ng/ml while using NRT and remaining abstinent 
(p =  .045). Participants with the highest cotinine measurements when smoking also tended to have the steepest reduction in 
cotinine levels while using NRT. This was most noticeable among participants with baseline cotinine levels more than 150 ng/
ml (n = 9) who had a greater reduction in median cotinine levels (median difference −134.8 ng /ml [95% CI = −144.5 to −125.9]) 
than those with a baseline cotinine level under 150 ng/ml (n = 24; median difference −27.9 ng/ml [95% CI = −49.35 to −1.75]).
Conclusions: In a pragmatic trial that replicated clinical practice, cotinine levels generated using NRT in pregnancy were 
lower than levels achieved from smoking. Although the sample size of this study was small, our findings are significant and are 
consistent with the hypothesis that NRT patches deliver an inadequate dose of nicotine to aid smoking cessation in pregnancy.
iNtrodUCtioN
Smoking in pregnancy is strongly associated with adverse 
pregnancy and birth outcomes (Cnattingius, 2004; Dechanet 
et al., 2011; Jaddoe et al., 2008; Li & Daling, 1991). In the 
United Kingdom, 26% of women smoke at some point during 
pregnancy and 12% of women continue to smoke throughout 
(The NHS Information Centre, 2011). Nicotine replacement 
therapy (NRT) in combination with behavioral support is 
often used to help pregnant smokers quit smoking (National 
Institute for Clinical Excellence, 2010). NRT is thought to 
be safer than smoking, as it does not contain all of the toxins 
present in tobacco smoke, and delivers only nicotine in doses 
aimed at relieving withdrawal symptoms (Benowitz et  al., 
2000).
NRT is effective in nonpregnant smokers (Stead, 
Bergson, & Lancaster, 2008), but its efficacy is unproven 
in pregnancy (Coleman, Chamberlain, Davey, Cooper, & 
Leonardi-Bee, 2012). Cotinine is the major metabolite of 
nicotine and is a specific marker for assessing nicotine 
exposure (Benowitz, Hukkanen, & Jacob, 2009). Nicotine 
is metabolized more rapidly in pregnancy, with a reported 
60% increase in nicotine clearance and 140% increase in 
cotinine clearance, obtained by both plasma and urinary 
measurement (Dempsey, Jacob, & Benowitz, 2002). This 
faster metabolism could mean the nicotine supplied from 
a standard NRT patch is insufficient to alleviate smoking 
withdrawal symptoms in pregnancy.
This study has used data from a trial of NRT in pregnancy, 
which attempted to replicate routine clinical practice, to 
compare the cotinine levels in women generated by smok-
ing with those from using NRT transdermal patches while 
abstinent.
MethodS
Data for this secondary analysis are from a double-blind, ran-
domized placebo-controlled study: the Smoking, Nicotine, 
and Pregnancy (SNAP) trial. The trial recruited 1050 women 
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from antenatal clinics within U.K. hospitals and investigated 
NRT 15 mg/16 hr transdermal patch use in pregnant smokers 
(n = 521) compared with placebo patches (n = 529; Coleman 
et al., 2012). The trial had a pragmatic design and intended, as 
far as possible, to mimic routine clinical practice; a descrip-
tion is available elsewhere (Coleman, Cooper, et al., 2012).
Participants were included in SNAP if they smoked ≥5 ciga-
rettes/day and ≥10 prior to pregnancy, were 12–24-weeks preg-
nant, were aged 16–45 years, and had an exhaled carbon monoxide 
reading (CO) of ≥8 p.p.m.  After enrolment, data on sociodemo-
graphics and smoking behavior were asked, and saliva cotinine 
was measured. Women were initially given a 4-week NRT supply 
to start on their quit date, followed by another 4-weeks’ supply 
if they were abstinent, confirmed by an exhaled CO reading of 
<8 p.p.m. Women were instructed to remove patches at night and 
discontinue them if they restarted smoking.
At 1  month, women who reported not smoking (≤5 ciga-
rettes smoked since quit date) had their abstinence validated by 
exhaled CO readings; those with validated abstinence, and who 
were also still using patches, were asked for a saliva sample 
to measure cotinine levels. Adherence with NRT trial patches 
between quit date and follow up was calculated as the total 
number of days the participant reported using the trial patches 
as a percentage of the length of time between the participant’s 
quit date and their follow-up appointment.
We wanted to perform analyses on participants who 
were allocated to NRT and who were reasonably adherent. 
Consequently, we included in analyses, women from the NRT 
group with validated abstinence, who reported at least 80% 
adherence with NRT (defined previously). This final criterion 
was used to ensure that participants were pregnant women 
using NRT on a regular basis.
Salivary cotinine levels were not normally distributed and 
were analyzed using nonparametric statistics; within-subject 
changes in cotinine levels between baseline and 1 month were 
analyzed using the Wilcoxon rank sum test.
reSULtS
Of the 521 women in the NRT arm of the trial, 131 self-reported 
smoking abstinence at 1 month and 111 permitted a research 
midwife to visit them to validate their abstinence using an 
exhaled CO reading. A total of 55 women were excluded due to 
low self-reported adherence to taking NRT (<80% adherence) 
and 23 women did not have a before and after cotinine meas-
urement to compare and subsequently were excluded. This left 
a sample size of 33 women.
Participant characteristics are presented using the median 
and interquartile ranges (IQRs) for the eligible 33 participants 
(Table 1). The participants were White British women, with the 
exception of one participant who was from an Asian/other back-
ground. They were on average 26 years old at recruitment. Most 
(67%) smoked 5–10 cigarettes/day prior to beginning the trial. 
All participants were in the second trimester of pregnancy at 
recruitment with the median gestational age being 14.4 weeks. 
We looked at how many of our sample stopped smoking in 
the SNAP trial, and nine participants (27%) were validated as 
abstinent from smoking at delivery.
The median cotinine level for participants while smoking at 
baseline was 98.5 ng/ml (IQR 71.3–177.8) and while abstinent 
and using NRT at 1  month was 62.8 ng/ml (IQR 33.3–82.7). 
There was a significant reduction in cotinine levels between base-
line when smoking and 1 month while using NRT (median dif-
ference −54.2 ng/ml, [95% CI = −70.5 to −25.5 ng/ml], p = .045). 
The majority of participants had cotinine levels at 1 month, which 
were lower than their levels at baseline (n = 27); six participants 
had cotinine levels at 1 month, which were higher than baseline.
Of the 33 participants, 17 participants reported no smok-
ing at all between their quit date and 1-month follow up, and 
the remaining 16 participants reported smoking five times or 
less. Six of the 16 participants reported smoking a cigarette in 
the 24 hr before their 1-month visit. We performed sensitivity 
analysis on the 27 women who had not smoked in the previous 
24 hr before the 1-month visit; the median difference in coti-
nine levels in this group was similar to that of the whole group 
−46.6 ng/ml (95% CI = −125 to −24.1 ng/ml).
We found a significant, positive correlation between base-
line and 1-month cotinine levels, Spearman correlation coef-
ficient ρ 0.35 (p =  .04). Although the association was weak, 
it suggests that participants with the highest baseline levels in 
the study also tended to have higher 1 month levels. However, 
the scatter plot (Figure 1) shows that for the majority of par-
ticipants (n = 27), cotinine levels at 1 month were lower than 
at baseline. The scatter plot also demonstrates that partici-
pants in the highest range of baseline cotinine levels appear 
to have the greatest reduction in 1-month cotinine levels. This 
is most noticeable among participants with baseline cotinine 
levels more than 150 ng/ml (n  =  9); these participants had a 
greater reduction in median cotinine levels (median difference 
−134.8 ng/ml [95% CI  =  −144.5 to −125.9]) compared with 
table 1. Participant Characteristics
Characteristics
Women included  
in study (n = 33),  
median (interquartile 
range or %)
Age (median, 25% and 75%) 26.12 (22.29–32.35)
Ethnicity
 White British 31 (98%)
 Asian background 1 (2%)
Body mass index 25.6 (22.7–29.3)
Age left full time education (years) 16 (16–17)
Gestational age at baseline (weeks) 14.4 (13.3–17.8)
Current cigarettes smoking per day
 5–10 22 (67%)
 11–15 8 (24%)
 16–20 –
 >20 3 (9%)
Heaviness of Smoking Index 3 (2–3)
Partner smoking status
 Partner smokes 23 (70%)
 Partner non smoking 6 (18%)
 No partner 4 (12 %)
Nicotine metabolite ratio 0.4 (0.3–0.5)
Adherence with NRT trial patcha
 80%–99% 12 (37%)
 100% 20 (63%)
Cotinine level baseline (ng/ml) 98.5 (71.3–177.8)
Cotinine level 1 month (ng/ml) 62.8 (33.3–82.7)
Validated smoking abstinent at delivery 9 (27%)
Note. NRT = nicotine replacement therapy. a% of days used 
trial patch from baseline to 1-month follow up. 
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those with a baseline cotinine level under 150 ng/ml (n = 24; 
median difference −27.9 ng/ml [95% CI = −49.35 to−1.75]).
diSCUSSioN
Main Findings
Our findings have shown that cotinine levels generated using 
NRT transdermal patches in pregnancy are lower than cotinine 
levels generated while smoking. Although these findings arise 
from a clinical trial, this had a relatively pragmatic design and 
was intended to replicate how NRT is used in routine clinical 
practice. We found a correlation between baseline and 1-month 
cotinine levels and observed that participants in the highest range 
of cotinine measurements at baseline (>150 ng/ml) tended to 
have the steepest reduction in cotinine levels while using NRT.
A strength of our study design was that it accounted for 
within-person differences and, therefore, change in cotinine 
levels will not have been influenced by inter-participant vari-
ation (e.g., in nicotine metabolic rate). We were also able to 
observe cotinine levels generated in a setting, which is similar 
to routine clinical practice, while also only including abstinent 
women who adhered to patches, so cotinine levels are very 
likely based on regular and continuous NRT use.
For unknown reasons, as in other randomized controlled 
trials, compliance with NRT in SNAP was low (Pollak et  al., 
2007; Wisborg, Henriksen, Jespersen, & Secher, 2000) and, as 
our analyses included only women who used patches regularly, 
cotinine levels measured are unlikely to reflect those generated 
in women using NRT intermittently. Additionally, it could be 
speculated that women who were excluded from the analysis 
might have lower cotinine levels than those included. In order 
for NRT to effective, it is expected that cotinine levels achieved 
from using NRT would need to be similar to those achieved by 
smoking (Benowitz, Zevin, & Jacob, 1997). Such lower cotinine 
levels could have caused these women to suffer from more with-
drawal symptoms, making them more likely to re-start smok-
ing and stop using patches, resulting in their exclusion. A final 
weakness of our study is that cotinine measurements on NRT 
and when smoking were taken 1  month apart; if, as research 
suggests, nicotine metabolism increases during pregnancy 
(Dempsey et  al., 2002), then this may partially explain lower 
cotinine levels seen when using NRT at the 1-month follow up. 
It could be speculated that NRT may have become increasingly 
insufficient as gestation increased, which is why only nine of the 
33 women had validated smoking abstinence at delivery.
Smaller laboratory-based studies have been able to report 
on the paired difference while using NRT. In one study, 
researchers administered 15 mg/16 hr patch over 5 days and 
found cotinine levels were 48% less than those achieved when 
smoking (p  =  .029) (Oncken, Campbell, Chan, Hatsukami, 
& Kranzler, 2009); our findings are consistent with this. 
However, another study that used patches over 5  days 
(Oncken et al., 1997) and a study that applied patches over an 
8-hr period (Ogburn et al., 1999) did not. It is possible that, in 
pregnancy, use of NRT for longer than 8 hr is required before 
stable cotinine levels are generated. Although informative, 
these studies were laboratory based and may not accurately 
represent cotinine levels achieved from using NRT in routine 
clinical practice.
Trials exploring the effects of NRT have reported lower 
cotinine levels in pregnant women randomized to NRT than 
those randomized to placebo; they have also reported lower 
levels after randomization to NRT than prior to study enrol-
ment (Oncken et  al., 2008; Wisborg et  al., 2000). However, 
these studies have not restricted comparisons to those women 
who achieved abstinence from smoking; consequently, these 
comparisons may reflect cotinine levels generated by smoking, 
NRT use, or both.
CoNCLUSioNS
In summary, in pregnancy, cotinine levels generated by 
15 mg/16 hr nicotine patches are lower than those generated by 
smoking. Although the sample size of this study was small, our 
results are significant. They do indicate that an apparently low 
level of nicotine substitution may be insufficient for NRT to 
have efficacy in pregnancy and may, at least partially, explain 
why standard dose NRT used by pregnant women has not been 
shown to be effective.
0
50
100
150
200
250
0 100 200 300
C
o
ti
n
in
e 
o
n
e 
m
o
n
th
 n
g
/m
l
Cotinine baseline ng/ml
figure 1. Cotinine levels at baseline while smoking and at 1 month while abstinent and using nicotine replacement therapy. 
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